Alexion Pharmaceuticals The biopharmaceutical company is scheduled to report fourth-quarter earnings on Feb. 9. Analysts, on average, expect profit of 34 cents a share on revenue of $220.8 million. "We believe ALXN can achieve strong top-line growth relative to biotech peers, based on Soliris' market potential in PNH and other indications," Oppenheimer analysts wrote in a Jan. 23 report. "Near term, we expect ALXN to continue to drive robust Soliris sales growth in PNH through strong commercial execution and geographic expansion." Shares of Alexion Pharmaceuticals hit a 52-week high of $78.05 on Wednesday. The stock's 52-week low of $41.65 was on Feb. 4. TheStreet Ratings gives Alexion a B+ grade with a $98.37 price target. The stock has increased 8.24% year to date.